Stock Analysis Report

Executive Summary

Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally.



Established dividend payer with mediocre balance sheet.

Similar Companies

Share Price & News

How has Quest Diagnostics's share price performed over time and what events caused price changes?

Latest Share Price and Events

Market Performance

7 Day Return




US Healthcare


US Market

1 Year Return




US Healthcare


US Market

Return vs Industry: DGX exceeded the US Healthcare industry which returned -9.4% over the past year.

Return vs Market: DGX underperformed the US Market which returned 6.7% over the past year.

Share holder returns

7 Day-1.1%0.6%1.0%
30 Day-0.8%-3.3%-1.8%
90 Day2.0%-8.9%-1.8%
1 Year5.9%3.6%-8.0%-9.4%9.1%6.7%
3 Year32.3%24.7%30.0%24.8%46.1%36.6%
5 Year92.1%73.5%60.1%50.5%66.9%48.6%

Price Volatility Vs. Market

How volatile is Quest Diagnostics's share price compared to the market and industry in the last 5 years?

Simply Wall St News


Is Quest Diagnostics undervalued based on future cash flows and its price relative to the stock market?


Price to Earnings (PE) ratio

Intrinsic Value Based on Future Cash Flows

Undervalued: DGX ($103.52) is trading above our estimate of fair value ($88.94)

Significantly Undervalued: DGX is trading above our estimate of fair value.

Price Based on Earnings

PE vs Industry: DGX is good value based on its PE Ratio (19.8x) compared to the Healthcare industry average (19.9x).

PE vs Market: DGX is poor value based on its PE Ratio (19.8x) compared to the US market (17.5x).

Price Based on Expected Growth

Low PEG Ratio: DGX is poor value based on its PEG Ratio (3.2x)

Price Based on Value of Assets

PB vs Industry: DGX is overvalued based on its PB Ratio (2.6x) compared to the US Healthcare industry average (2.4x).

Next Steps

Future Growth

How is Quest Diagnostics expected to perform in the next 1 to 3 years based on estimates from 18 analysts?


Forecasted annual earnings growth

Earnings and Revenue Growth Estimates

Future Annual Growth Analysis

Earnings vs Savings Rate: DGX's forecast earnings growth (6.2% per year) is above the savings rate (2.7%).

Earnings vs Market: DGX's earnings (6.2% per year) are forecast to grow slower than the US market (14.5% per year).

High Growth Earnings: DGX's earnings are forecast to grow, but not significantly.

Revenue vs Market: DGX's revenue (2% per year) is forecast to grow slower than the US market (7.3% per year).

High Growth Revenue: DGX's revenue (2% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Estimates

Future Return on Equity

High Future ROE: DGX's Return on Equity is forecast to be low in 3 years time (13.3%).

Next Steps

Past Performance

How has Quest Diagnostics performed over the past 5 years?


Historical annual earnings growth

Earnings and Revenue History

Past Earnings Growth Analysis

Earnings Trend: DGX's earnings have grown by 5.4% per year over the past 5 years.

Accelerating Growth: DGX's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: DGX had negative earnings growth (-12.5%) over the past year, making it difficult to compare to the Healthcare industry average (5.3%).

Return on Equity

High ROE: DGX's Return on Equity (13.6%) is considered low.

Return on Assets

ROA vs Industry: DGX has a higher Return on Assets than the Healthcare industry average last year.

Return on Capital Employed

ROCE Improving: DGX's Return on Capital Employed has declined over the past 3 years.

Next Steps

Financial Health

How is Quest Diagnostics's financial position?

Financial Position Analysis

Short Term Liabilities: DGX's short term assets ($1.6B) do not cover its short term liabilities ($1.9B)

Long Term Liabilities: DGX's short term assets (1.6B) do not cover its long term liabilities (4.3B)

Debt to Equity History and Analysis

Debt Level: DGX's debt to equity ratio (71.2%) is considered high

Reducing Debt: DGX's debt to equity ratio has reduced from 95.6% to 71.2% over the past 5 years.

Debt Coverage: DGX's debt is well covered by operating cash flow (32.5%).

Interest Coverage: DGX's interest payments on its debt are well covered by EBIT (6.7x coverage).

Balance Sheet

Inventory Level: DGX has a low level of unsold assets or inventory.

Debt Coverage by Assets: DGX's debt is not covered by short term assets (assets are 0.4x debt).

Next Steps


What is Quest Diagnostics's current dividend yield, its reliability and sustainability?


Expected Dividend Yield

Dividend Yield vs Market


Current dividend yield vs market & industry

Dividend Yield and Payments Analysis

Notable Dividend: DGX's dividend (2.05%) is higher than the bottom 25% of dividend payers in the US market (1.46%).

High Dividend: DGX's dividend (2.05%) is low compared to the top 25% of dividend payers in the US market (3.77%).

Stable Dividend: DGX's dividends per share have been stable in the past 10 years.

Growing Dividend: DGX's dividend payments have increased over the past 10 years.

Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (39.9%), DGX's dividend payments are well covered by earnings.

Future Payout to Shareholders

Future Dividend Coverage: DGX's dividends in 3 years are forecast to be well covered by earnings (30.7% payout ratio).

Next Steps


What is the CEO of Quest Diagnostics's salary, the management and board of directors tenure and is there insider trading?


Average management tenure


Steve Rusckowski (62yo)





Mr. Stephen H. Rusckowski, also known as Steve, has been the Chief Executive Officer and President of Quest Diagnostics Incorporated since May 01, 2012 and has been its Chairman since January 01, 2017. Mr. ...

CEO Compensation Analysis

Compensation vs. Market: Steve's total compensation ($USD9.95M) is about average for companies of similar size in the US market ($USD11.20M).

Compensation vs Earnings: Steve's compensation has been consistent with company performance over the past year.

Management Age and Tenure


Average Tenure


Average Age

Experienced Management: DGX's management team is seasoned and experienced (6.4 years average tenure).

Board Age and Tenure


Average Tenure


Average Age

Experienced Board: DGX's board of directors are considered experienced (5.3 years average tenure).

Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Management Team

  • Steve Rusckowski (62yo)


    • Tenure: 7.4yrs
    • Compensation: US$9.95m
  • Michael Prevoznik (57yo)

    Senior VP & General Counsel

    • Tenure: 20.2yrs
    • Compensation: US$2.09m
  • Catherine Doherty (56yo)

    Senior VP and Group Executive of Clinical Franchise Solutions & Marketing

    • Tenure: 0yrs
    • Compensation: US$2.32m
  • Shawn Bevec

    Vice President of Investor Relation

    • Tenure: 0yrs
  • Gabrielle Wolfson

    Senior VP and Chief Information & Digital Officer

    • Tenure: 0.7yrs
  • Tim Sharpe

    Vice President of Compliance

    • Tenure: 19.8yrs
  • Mark Guinan (57yo)

    Executive VP & CFO

    • Tenure: 6.3yrs
    • Compensation: US$3.23m
  • Carrie Manner (44yo)

    Senior Vice President of Advanced Diagnostics

    • Tenure: 2.7yrs
    • Compensation: US$2.89m
  • Jim Davis (56yo)

    Executive Vice President of General Diagnostics

    • Tenure: 6.5yrs
    • Compensation: US$3.07m
  • Michael Deppe (53yo)

    VP, Corporate Controller

    • Tenure: 0.5yrs

Board Members

  • Tim Main (62yo)

    Independent Director

    • Tenure: 5.8yrs
    • Compensation: US$284.98k
  • Steve Rusckowski (62yo)


    • Tenure: 7.4yrs
    • Compensation: US$9.95m
  • Tim Ring (61yo)

    Independent Director

    • Tenure: 7.8yrs
    • Compensation: US$291.48k
  • Gary Pfeiffer (69yo)

    Independent Director

    • Tenure: 14.8yrs
    • Compensation: US$316.48k
  • Gail Wilensky (76yo)

    Independent Director

    • Tenure: 22.8yrs
    • Compensation: US$298.48k
  • Dan Stanzione (73yo)

    Lead Independent Director

    • Tenure: 2.8yrs
    • Compensation: US$333.98k
  • Denise Morrison (65yo)

    Independent Director

    • Tenure: 0.7yrs
  • Vicky Gregg (64yo)

    Independent Director

    • Tenure: 5.3yrs
    • Compensation: US$280.98k
  • Helen Torley (56yo)

    Independent Director

    • Tenure: 1.4yrs
    • Compensation: US$232.67k

Company Information

Quest Diagnostics Incorporated's company bio, employee growth, exchange listings and data sources

Key Information

  • Name: Quest Diagnostics Incorporated
  • Ticker: DGX
  • Exchange: NYSE
  • Founded: 1967
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: US$13.941b
  • Shares outstanding: 134.67m
  • Website: https://www.questdiagnostics.com

Number of Employees


  • Quest Diagnostics Incorporated
  • 500 Plaza Drive
  • Secaucus
  • New Jersey
  • 7094
  • United States


TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
DGXNYSE (New York Stock Exchange)YesCommon StockUSUSDDec 1996
QDIDB (Deutsche Boerse AG)YesCommon StockDEEURDec 1996
0KSXLSE (London Stock Exchange)YesCommon StockGBUSDDec 1996
DGX *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNDec 1996


Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic testing information and services ...

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/14 01:16
End of Day Share Price2019/10/11 00:00
Annual Earnings2018/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Copyright © 2018, Standard & Poor’s Financial Services LLC. Reproduction of S&P Capital IQ in any form is prohibited except with the prior written permission of S&P. S&P does not guarantee the accuracy, adequacy, completeness or availability of any information and is not responsible for any errors or omissions, regardless of the cause or for the results obtained from the use of such information. S&P DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall S&P be liable for any direct, indirect, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or lost profit and opportunity costs) in connection with subscriber’s or others’ use of S&P Capital IQ. (2018)